Wada (Intracarotid Amobarbital) Procedure: Clinical Applications

Wednesday, March 4, 2015
12:00pm – 1:30pm Eastern time
1.5 CE Credits 

Presented by:
Gregory P. Lee, Ph.D., ABPP-CN
Professor, Department of Neurology, School of Medicine
Professor, School of Allied Health Sciences and School of Graduate Studies
Georgia Health Sciences University

Wada testing is an established method to lateralize language and memory functions prior to epilepsy surgery in an attempt to prevent postoperative aphasia and memory loss.  Wada memory testing has also become useful in corroborating the side of seizure onset and assisting in the prediction of seizure-relief outcome.  This webinar will describe in detail the current most widely utilized Wada testing protocol for assessing language and memory after amobarbital administration as well as the related angiography procedures and how to analyze results and make surgical recommendations.  Discussion regarding potential confounding factors, such as angiographic cross-flow, fetal origin arteries, antiepileptic drugs that may reduce amobarbital potency, seizures during the procedure, and severe behavioral reactions will be reviewed.  The pros and cons of using drugs other than amobarbital will be briefly considered and the status of the Wada in light of the newer, less invasive procedures, such as functional MRI and magnetoencephalography will also be covered.
 
After the webinar, participants will be able to:
  1. Describe the cognitive testing methods used to evaluate language and memory during the Wada procedure.
  2. Analyze common Wada test result patterns and apply them to surgical recommendations.
  3. List the major problems than can arise during the Wada and select procedures that help reduce their impact.
  4. List the medical diagnostic procedures that will most likely replace Wada testing eventually and describe their current shortcomings.
Target Audience: Clinical neuropsychologists and students of neuropsychology (residents, interns, graduate students) who are interested in epilepsy surgery practice.
 
Instructional Level: Intermediate-to-Advanced

Gregory P. Lee, PhD, ABPP is a Professor of Neurology in the Medical College of Georgia at Georgia Regents University.  He is board-certified in Clinical Neuropsychology by ABPP/ABCN and a fellow of the American Psychological Association and the National Academy of Neuropsychology.  Dr. Lee is the Director of Adult Neuropsychological Services for the Departments of Neurology and Neurosurgery at the Medical College of Georgia, and he teaches courses in the behavioral neurosciences for medical, allied health, and neuroscience graduate students and neurology residents.  Professor Lee is also an active researcher with over 150 publications primarily in the areas of clinical epilepsy and epilepsy surgery, and author of the book, Neuropsychology of Epilepsy & Epilepsy Surgery, published by Oxford University Press.


NAN members login and non-members create an account to:





Effects of Alcohol on Cognitive Functioning

Wednesday, April 15, 2015
12:00pm – 1:30pm Eastern time
1.5 CE Credits 

Presented by:
Robin C. Hilsabeck, Ph.D., ABPP
Clinical Scientist II at INC Research
Associate Clinical Professor of Psychiatry at University of Texas Health Science Center in San Antonio

Approximately 17 million adults and 855,000 adolescents had an alcohol use disorder (AUD) in 2012.  Deaths related to alcohol are the third leading cause of preventable death in the U.S.  Given these statistics, almost all neuropsychologists will be faced at some point with a patient who has an AUD. Understanding both the acute and chronic effects of alcohol on cognitive functioning is a primary objective of this webinar. Recent advances in neuropathophysiology, as well as common findings on neuroimaging and neuropsychological tests are reviewed.  The evolution from chronic alcohol use to Wernicke’s encephalopathy to Korsakoff’s syndrome is discussed, along with the effects of alcohol use in special populations, including adolescents and elderly. Risk factors, comorbidity, emerging pharmacotherapies, and cognitive rehabilitation strategies are also highlighted.
 
After the webinar, participants will be able to:
  1. Explain cognitive abilities affected by acute and chronic alcohol use.
  2. Describe the role of thiamine deficiency in cognitive impairment associated with AUDs.
  3. Differentiate between cognitive profiles of chronic alcohol use and Korsakoff’s syndrome.
  4. Identify risk factors for AUDs in adolescents. 

Target Audience: Neuropsychologists, advanced neuropsychological trainees, physicians, psychologists, and other professionals with specialty training in AUDs
 
Instructional Level: Intermediate to Advanced (some prior knowledge of neuroanatomy, neurotransmitter systems, and neuropsychological constructs is expected)

Robin C. Hilsabeck, Ph.D., ABPP is a board certified clinical neuropsychologist who earned her Ph.D. in clinical psychology from Louisiana State University in 1999 with internship training in neuropsychology at University of Oklahoma Health Science Center. She completed a 2-year postdoctoral fellowship in neuropsychology at University of California, San Diego where she worked primarily with patients with chronic liver disease, including those with alcohol dependence and chronic hepatitis C infection.

Dr. Hilsabeck is Clinical Scientist II at INC Research, a contract research organization that assists in running global clinical trials.  She also is Associate Clinical Professor of Psychiatry at University of Texas Health Science Center in San Antonio where she has been on faculty since 2006.  From January 2005 through June 2012, she served in multiple roles at the South Texas Veterans Health Care System in San Antonio, including Director of the Neuropsychology Service and Director of the Neuropsychology Residency Program.  She continues to collaborate in clinical research at the VA in San Antonio. 

Dr. Hilsabeck has obtained grant funding from both private funders, as well as the NIH, and has 50 publications, including a recent book chapter on substance use in the edited book by Shane Bush entitled, “Neuropsychological Practice with Veterans.”  She is Associate Editor of The Clinical Neuropsychologist and serves on the editorial board of the Archives of Clinical Neuropsychology.  She also is Past President of the National Academy of Neuropsychology.

NAN members login and non-members create an account to:





Medication & Cognition

Wednesday, May 13, 2015
12:00pm – 1:30pm Eastern time
1.5 CE Credits 

Presented by:

Joseph E. Comaty, Ph.D., M.P.
Adjunct Assistant Professor in Psychology at Louisiana State University
Emeritus Faculty of the Southern Louisiana Internship Consortium in Psychology at Louisiana State University

This course is designed to provide the audience with the most up-to-date information on those psychotropic medications often misused in older adults. The course will cover identification of the medications in the classes of antipsychotics, antidepressants, benzodiazepines, non-benzodiazepine hypnotics, stimulants, cognitive enhancers, and acetylcholinesterase inhibitors.  The audience will be provided information on the indications for the use of these classes of medications and their most common adverse effects, particularly as experienced by older adults especially those with dementia.  Finally, the course will provide the audience with a summary of the BEERS criteria and other initiatives that have attempted to reduce the use of potentially inappropriate medications in the population of older adults.
 
After the webinar, participants will be able to:

  1. Describe the most commonly used psychotropic drugs in the elderly.
  2. Discuss the difference between the current use of psychotropic drugs versus their FDA indications.
  3. Explain the most frequently encountered adverse effects of the currently used psychotropic drugs, especially the impact on cognition.
  4. Discuss the effectiveness of psychotropic medications in treating psychiatric/behavioral disorders of the elderly including risk / benefit ratios. 

Target Audience: This presentation is designed for prescribing psychologists; psychologists who work with older adults in a variety of clinical settings; psychologists who may be conducting research on medication effects in the elderly; or psychologists who are teaching courses on psychopharmacology and/or behavioral health treatment of special populations including the elderly. Other behavioral health practitioners may also benefit from the information provided in this course.
 
Instructional Level: Intermediate

Joseph E. Comaty received his M.S. in experimental psychology from Villanova University; his Ph.D. in psychology with a specialization in clinical neuropsychology from the Rosalind Franklin University of Medicine and Science, in Illinois; and his postdoctoral Masters Degree in clinical psychopharmacology from Alliant University/CSPP of California. He is a licensed psychologist under the Louisiana State Board of Examiners of Psychologists (LSBEP) and a licensed Medical Psychologist (i.e., prescribing psychologist) under the Louisiana State Board of Medical Examiners. He retired from the Louisiana Department of Health and Hospitals, Office of Behavioral Health in 2013 where he was the Chief Psychologist and Medical Psychologist and Director of the Division of Quality Management. He is an adjunct assistant professor in psychology at Louisiana State University (LSU) in Baton Rouge and serves as emeritus faculty of the Southern Louisiana Internship Consortium (SLIC) in psychology at LSU. He is currently serving a second term as member of the LSBEP where he was previously a member and past chair; he has just completed his term as a charter member and most recent chair of the RxP Designation Committee of APA, and is a current site reviewer for APA’s Committee on Accreditation. He is a member of the Model Act and Regulation Revision Committee for the Association of State and Provincial Psychology Boards (ASPPB). His research is in the areas of behavior therapy, pharmacology, and clinical psychopharmacology. He is the author of over 60 articles, book chapters, and presentations. He is a co-author of the psychopharmacology textbook, Julien’s Primer of Drug Action, the most recent edition being published in April 2014. He has served on federal grant review committees and has been a reviewer for Psychiatric Services; The Journal of Gerontology: Psychological Sciences; the Journal of Behavioral Health Services and Research; and the Journal of Psychology & Clinical Psychiatry.

NAN members login and non-members create an account to: